Papp L Roy & Associates Makes New $204,000 Investment in Zoetis Inc (NYSE:ZTS)
Papp L Roy & Associates bought a new position in shares of Zoetis Inc (NYSE:ZTS) during the 3rd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor bought 1,640 shares of the company’s stock, valued at approximately $204,000.
Several other large investors also recently bought and sold shares of ZTS. Nuveen Asset Management LLC lifted its position in shares of Zoetis by 40,874.9% during the second quarter. Nuveen Asset Management LLC now owns 7,078,826 shares of the company’s stock worth $803,376,000 after acquiring an additional 7,061,550 shares in the last quarter. Stonehage Fleming Financial Services Holdings Ltd purchased a new stake in shares of Zoetis during the second quarter worth $133,113,000. Bank of New York Mellon Corp lifted its position in shares of Zoetis by 9.5% during the second quarter. Bank of New York Mellon Corp now owns 4,420,261 shares of the company’s stock worth $501,654,000 after acquiring an additional 383,799 shares in the last quarter. Vanguard Group Inc. lifted its position in shares of Zoetis by 1.0% during the second quarter. Vanguard Group Inc. now owns 36,765,577 shares of the company’s stock worth $4,172,526,000 after acquiring an additional 346,167 shares in the last quarter. Finally, Natixis lifted its position in shares of Zoetis by 147.1% during the second quarter. Natixis now owns 547,078 shares of the company’s stock worth $62,088,000 after acquiring an additional 325,661 shares in the last quarter. Hedge funds and other institutional investors own 89.95% of the company’s stock.
In other Zoetis news, EVP Roxanne Lagano sold 4,463 shares of the firm’s stock in a transaction dated Monday, August 19th. The stock was sold at an average price of $125.99, for a total transaction of $562,293.37. Following the sale, the executive vice president now owns 33,190 shares in the company, valued at $4,181,608.10. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, EVP Kristin C. Peck sold 11,500 shares of the firm’s stock in a transaction dated Monday, August 12th. The shares were sold at an average price of $123.22, for a total value of $1,417,030.00. Following the sale, the executive vice president now owns 48,877 shares in the company, valued at approximately $6,022,623.94. The disclosure for this sale can be found here. Insiders sold 34,332 shares of company stock worth $4,258,182 in the last quarter. 0.29% of the stock is currently owned by company insiders.
Zoetis (NYSE:ZTS) last issued its quarterly earnings data on Thursday, November 7th. The company reported $0.94 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $0.88 by $0.06. Zoetis had a return on equity of 72.86% and a net margin of 22.74%. The company had revenue of $1.58 billion for the quarter, compared to the consensus estimate of $1.58 billion. During the same quarter last year, the business posted $0.83 earnings per share. The firm’s revenue was up 7.0% compared to the same quarter last year. Research analysts expect that Zoetis Inc will post 3.57 EPS for the current year.
The firm also recently disclosed a quarterly dividend, which will be paid on Monday, December 2nd. Investors of record on Tuesday, October 22nd will be given a $0.164 dividend. The ex-dividend date is Monday, October 21st. This represents a $0.66 dividend on an annualized basis and a dividend yield of 0.56%. Zoetis’s dividend payout ratio (DPR) is presently 21.09%.
ZTS has been the topic of several recent research reports. Stifel Nicolaus set a $140.00 target price on Zoetis and gave the stock a “buy” rating in a research report on Friday, September 13th. Barclays increased their target price on Zoetis from $120.00 to $135.00 and gave the stock an “overweight” rating in a research report on Wednesday, August 7th. Morgan Stanley increased their target price on Zoetis from $100.00 to $136.00 and gave the stock an “equal weight” rating in a research report on Monday, September 30th. Goldman Sachs Group initiated coverage on Zoetis in a research report on Monday, September 9th. They set a “conviction-buy” rating and a $145.00 target price on the stock. Finally, Credit Suisse Group set a $138.00 target price on Zoetis and gave the stock a “buy” rating in a research report on Friday, October 11th. Eight analysts have rated the stock with a hold rating, eight have given a buy rating and one has issued a strong buy rating to the stock. Zoetis has an average rating of “Buy” and a consensus price target of $126.75.
Zoetis Company Profile
Zoetis Inc discovers, develops, manufactures, and commercializes animal health medicines, vaccines, and diagnostic products in the United States and internationally. It commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep; and companion animals comprising dogs, cats, and horses.
Recommended Story: Fundamental Analysis – How It Helps Investors
Want to see what other hedge funds are holding ZTS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Zoetis Inc (NYSE:ZTS).
Receive News & Ratings for Zoetis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zoetis and related companies with MarketBeat.com's FREE daily email newsletter.